AVTX — Avalo Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1534120 ·
Last close
$19.27
Market Cap
$1.03B
52W High
$21.02
52W Low
$12.52
ADV30
791,661
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -31,517,000 | -36,358,000 | 490,783,000 | 85,382,000 | 42,123,000 |
| Mar 2026 | 0 | — | -20,901,000 | -19,630,000 | 99,885,000 | 24,988,000 | 31,565,000 |
| Dec 2025 | 59,000 | 59,000 | -19,742,000 | -13,720,000 | 116,458,000 | 15,858,000 | 33,409,000 |
| Sep 2025 | 0 | 0 | -19,198,000 | -30,625,000 | 125,100,000 | 26,963,000 | 33,553,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-68,290,000
Investing CF
$-315,280,000
Financing CF
$426,664,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.92
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-504,510,000
Inventory
—
Receivables
$611,000
ST Investments
$314,894,000
EBIT TTM
$-91,358,000
Pretax Income TTM
$-100,162,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$59,000
EBITDA
$-91,251,000
Free Cash Flow
$-23,271,000
Enterprise Value
$663,448,704
Total Cash
$400,276,000
Total Debt
$242,000
Shares Out
53,629,989
Trailing EPS
$-4.41
Book Value
$8.48
ROE
-36.3%
ROA
-18.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 59,000 | -72,925,000 | -78,259,000 | 116,458,000 | 33,409,000 | — | -51,458,000 |
| Dec 2024 | 441,000 | -40,871,000 | -35,129,000 | 150,732,000 | 17,700,000 | — | -49,056,000 |
| Dec 2023 | 1,924,000 | -23,444,000 | -31,544,000 | 20,993,000 | 13,689,000 | — | -30,680,000 |
| Dec 2022 | 18,051,000 | -37,440,000 | -41,658,000 | 33,367,000 | 44,282,000 | — | -26,751,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$249,000
NetIncome TTM
$23,037,000
OpCashFlow TTM
$0
Assets (Latest)
$150,732,000
Forward EPS
$-2.63
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $19.27 · call volume: 129 · put volume: 1Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LXRX | LEXICON PHARMACEUTICALS, INC. | $1.03B | $2.32 | — |
| ABUS | Arbutus Biopharma Corp | $1.03B | $5.20 | — |
| SLNCF | Silence Therapeutics plc | $1.03B | $5.50 | — |
| WVE | Wave Life Sciences, Inc. | $1.01B | $5.12 | — |
| PCRX | Pacira BioSciences, Inc. | $978.19M | $24.86 | — |
News headlines (Yahoo Finance, 1h cache)
Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?
2026-08-11 09:12 · Yahoo
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
2026-08-06 11:00 · Yahoo
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
2026-07-22 11:00 · Yahoo
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
2026-07-07 11:00 · Yahoo
Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed
2026-06-30 01:07 · Yahoo
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
2026-06-26 11:00 · Yahoo
Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026
2026-06-23 15:36 · Yahoo
Avalo Therapeutics Appoints Ron Philip to Board of Directors
2026-06-23 11:00 · Yahoo
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
2026-06-16 11:00 · Yahoo
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
2026-05-22 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.